Chlamydia trachomatisSerology in Women with and without Ovarian Cancer | Zendy

Roberta B. Ness | Zendy; Caixia Shen | Zendy; Debra C. Bass | Zendy; Carlynn Jackson | Zendy; Kristen B. Moysich | Zendy; Robert P. Edwards | Zendy; Robert C. Brunham | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chlamydia trachomatisSerology in Women with and without Ovarian Cancer

Author(s) -

Roberta B. Ness,

Caixia Shen,

Debra C. Bass,

Carlynn Jackson,

Kristen B. Moysich,

Robert P. Edwards,

Robert C. Brunham

Publication year - 2008

Publication title -

infectious diseases in obstetrics and gynecology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.656

H-Index - 48

eISSN - 1098-0997

pISSN - 1064-7449

DOI - 10.1155/2008/219672

Subject(s) - chlamydia trachomatis , serology , chlamydia , ovarian cancer , gynecology , population , medicine , antibody , cancer , titer , pelvic inflammatory disease , odds ratio , immunology , environmental health

Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer ( n = 521) and population-based controls ( n = 766) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (≥0.40 OD units) were 0.6 (95% CI 0.4–0.9). These data do not support our earlier finding of elevated titers for antibodies to C. trachomatis among women with ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research